Clinical Trials
19 trialsNCT02559778 2026-04-28
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT02513667 2023-02-03
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT02186821 2021-04-08
SIGNATURE
Novartis
Phase 2 Terminated
NCT02450903 2021-03-30
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Novartis
Phase 2 Completed
NCT02276027 2020-12-16
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT02336451 2020-04-21
Ascend-7
Novartis
Phase 2 Completed
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated
NCT02465528 2019-12-27
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
Phase 2 Terminated
NCT02289144 2019-07-30
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01685138 2019-03-26
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT01964157 2019-01-11
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Yonsei University
Phase 2 Unknown
NCT03399487 2019-01-11
A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Yonsei University
Phase 2 Unknown
NCT02374489 2018-04-05
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
National Health Research Institutes, Taiwan
Phase 2 Terminated
NCT02638909 2018-04-02
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Criterium, Inc.
Phase 2 Terminated
NCT01685060 2017-06-19
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Novartis
Phase 2 Completed
NCT02343679 2017-02-01
Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Duke University
Phase 2 Withdrawn